Presza 50 Tablets

Presza 50 Tablets
 

COMPOSITION:

Azathioprine  50 mg

Introduction

Presza 50 tablet contains azathioprine. It is an immunosuppressant drug which produces its action by suppressing the response of immune system.

 

Indication

  • Skin rashes
  • Severe inflammatory skin diseases
  • Atopic dermatisis (Itchy red skin occurs in childhood occurs near by arms or knees)
  • Sarcoidosis (Inflammation of the cells causes lumps)
  • Eczema (Patchy or itchy skin which usually gets inflamed and even bleeds)

 

Dosage

Doses of the are as follows:
Atopic dermatitis:  2.5 mg/kg orally once a day, in the morning, for 3 months

Sarcoidosis:             2 mg/kg per day in combination with prednisolone 0.6 to 0.8 mg/kg per day

Eczema:                    2.5 to 3.5 mg/kg per day

 

Mechanism of action

The drug produces its immunosuppressant  action by inhibiting the synthesis of protein, DNA and RNA. It also interferes with the mitosis  by effecting cellular metabolism. Azathioprine produces its action by changing the structure of DNA due to the incorporation of thiopurine analogue.

 

 

 

 

Pharmacology

Absorption

The drug after oral administration absorbs well in the body. The drug  attains its maximum serum concentration within 1 to 2 hrs.

Distribution

The drug gets converted to its active metabolite by non- enzymatic process to metabolite            6 – mercaptopurine.  Hypoxanthine-guanine phosphoribosyltransferase causes the activation of the metabolite to form thioguanine nucleotides (6-TGNs) as a metabolite by involving multiple enzymatic processes involving kinase.

Excretion

In erythrocytes and liver the drug gets methylated or oxidized and gets rapidly eliminated from blood. The drug after 8 hrs are is not detectable in urine.

 

Contraindications

  • Hypersensitivity to any of the ingredient
  • Not be used for the treatment of the patients suffering from rheumatoid arthritis

 

Precaution

  • Discontinue the use of the drug if suffering from gastrointestinal hypersensitivity reaction characterized by nausea and vomiting.
  • Patient should be under regular analysis for complete blood count
  • Not to administered to pregnant patients
  • Not to be used in pediatric patient